FDAnews
www.fdanews.com/articles/176189-isoray-cans-gliasite-due-to-low-sales

IsoRay Cans GliaSite Due to Low Sales

April 13, 2016

IsoRay has bid adieu to its GliaSite radiation therapy system and certain ancillary products, following “marginal sales” since its introduction, the company announced in a regulatory filing.

IsoRay has issued notices to end licensing agreements with Dr. Reddy’s Laboratories and Hologic and has slashed a distribution agreement with Karlheinz Goehl-Medizintechnik Goehl.

The system is designed to deliver brachytherapy radiation to treat brain cancer. — Anisa Jibrell